Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | PPARD | Q03181 | 4/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | APEX1 | P27695 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3695827 | 0.93 | PPARD (0.51) | L3MBTL1PPARDPTGDR2ALDH1A1PTPN1 | |
| SCHEMBL3680331 | 0.93 | PTGDR2 (0.49) | L3MBTL1PPARDPTGDR2PTPN1MAPT | |
| SCHEMBL3687372 | 0.92 | L3MBTL1 (0.47) | L3MBTL1PPARDPTGDR2ALDH1A1KDM4E | |
| SCHEMBL3697015 | 0.89 | PPARD (0.52) | PPARDPTGDR2 | |
| SCHEMBL3690506 | 0.88 | PPARD (0.54) | PPARDPTPN1 | |
| SCHEMBL3687327 | 0.88 | PPARD (0.48) | L3MBTL1PPARDPTGDR2PTPN1 | |
| SCHEMBL3692145 | 0.87 | PPARD (0.47) | PPARDPTGDR2 | |
| SCHEMBL3681848 | 0.87 | KEAP1 (0.45) | PPARDPTGDR2PTPN1 | |
| SCHEMBL3681144 | 0.86 | PPARD (0.48) | PPARDPTGDR2GAAPTPN1MAPT | |
| SCHEMBL3692271 | 0.86 | PPARD (0.49) | PPARDPTGDR2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7655641-B2 | Sulfonamide derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| US-7655641-B2 | Sulfonamide derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| US-7655641-B2 | Sulfonamide derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| EP-1597248-B1 | SULFONAMIDE DERIVATIVES AS PPAR MODULATORS | LILLY CO ELI (US) | 2007-12-26 | — | — | EP | disclosed |
| EP-1597248-B1 | SULFONAMIDE DERIVATIVES AS PPAR MODULATORS | LILLY CO ELI (US) | 2007-12-26 | — | — | EP | disclosed |
| US-20060217433-A1 | Sulfonamide derivatives as ppar modulators | ELI LILLY AND COMPANY (US) | 2006-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217433-A1 | Sulfonamide derivatives as ppar modulators | PPARD, PPARA, PPARG | L3MBTL1 4653/4885PPARD 1/4885PTGDR2 328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.